Mostrar el registro sencillo del ítem
Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019
dc.contributor.author | Kocarnik, Jonathan | spa |
dc.contributor.author | Compton, Kelly | spa |
dc.contributor.author | Dean, Frances E | spa |
dc.contributor.author | Fu, Weijia | spa |
dc.contributor.author | Gaw, Brian L | spa |
dc.contributor.author | Harvey, James D | spa |
dc.contributor.author | Henrikson, Hannah | spa |
dc.contributor.author | Lu, Dan | spa |
dc.contributor.author | Pennini, Alyssa | spa |
dc.contributor.author | Xu, Rixing | spa |
dc.contributor.author | Alvis-Guzmán, Nelson | spa |
dc.contributor.author | Et al | spa |
dc.date.accessioned | 2022-07-26T18:59:38Z | |
dc.date.available | 2023 | |
dc.date.available | 2022-07-26T18:59:38Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Global Burden of Disease 2019 Cancer Collaboration. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022;8(3):420–444. doi:10.1001/jamaoncol.2021.6987 | spa |
dc.identifier.issn | 2374-2437 | spa |
dc.identifier.uri | https://hdl.handle.net/11323/9405 | spa |
dc.description.abstract | Importance The Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019) provided systematic estimates of incidence, morbidity, and mortality to inform local and international efforts toward reducing cancer burden. Objective To estimate cancer burden and trends globally for 204 countries and territories and by Sociodemographic Index (SDI) quintiles from 2010 to 2019. Evidence Review The GBD 2019 estimation methods were used to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life years (DALYs) in 2019 and over the past decade. Estimates are also provided by quintiles of the SDI, a composite measure of educational attainment, income per capita, and total fertility rate for those younger than 25 years. Estimates include 95% uncertainty intervals (UIs). Findings In 2019, there were an estimated 23.6 million (95% UI, 22.2-24.9 million) new cancer cases (17.2 million when excluding nonmelanoma skin cancer) and 10.0 million (95% UI, 9.36-10.6 million) cancer deaths globally, with an estimated 250 million (235-264 million) DALYs due to cancer. Since 2010, these represented a 26.3% (95% UI, 20.3%-32.3%) increase in new cases, a 20.9% (95% UI, 14.2%-27.6%) increase in deaths, and a 16.0% (95% UI, 9.3%-22.8%) increase in DALYs. Among 22 groups of diseases and injuries in the GBD 2019 study, cancer was second only to cardiovascular diseases for the number of deaths, years of life lost, and DALYs globally in 2019. Cancer burden differed across SDI quintiles. The proportion of years lived with disability that contributed to DALYs increased with SDI, ranging from 1.4% (1.1%-1.8%) in the low SDI quintile to 5.7% (4.2%-7.1%) in the high SDI quintile. While the high SDI quintile had the highest number of new cases in 2019, the middle SDI quintile had the highest number of cancer deaths and DALYs. From 2010 to 2019, the largest percentage increase in the numbers of cases and deaths occurred in the low and low-middle SDI quintiles. Conclusions and Relevance The results of this systematic analysis suggest that the global burden of cancer is substantial and growing, with burden differing by SDI. These results provide comprehensive and comparable estimates that can potentially inform efforts toward equitable cancer control around the world. | eng |
dc.format.extent | 25 páginas | spa |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | eng | |
dc.publisher | American Medical Association | spa |
dc.rights | Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0) | spa |
dc.rights | © 2022 American Medical | spa |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | spa |
dc.title | Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019 | eng |
dc.type | Artículo de revista | spa |
dc.source.url | https://jamanetwork.com/journals/jamaoncology/fullarticle/2787350 | spa |
dc.rights.accessrights | info:eu-repo/semantics/embargoedAccess | spa |
dc.identifier.doi | 10.1001/jamaoncol.2021.6987 | spa |
dc.identifier.eissn | 2374-2445 | spa |
dc.identifier.instname | Corporación Universidad de la Costa | spa |
dc.identifier.reponame | REDICUC - Repositorio CUC | spa |
dc.identifier.repourl | https://repositorio.cuc.edu.co/ | spa |
dc.publisher.place | United States | spa |
dc.relation.ispartofjournal | JAMA Oncology | spa |
dc.relation.references | 1. Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052-2090. doi:10.1016/S0140-6736(18)31694-5 | spa |
dc.relation.references | 2. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012;13(8):790-801. doi:10.1016/S1470-2045(12)70211-5 | spa |
dc.relation.references | 3. International Agency for Research on Cancer. World cancer report: cancer research for cancer prevention. Accessed March 1, 2021. https://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-Cancer-Research-For-Cancer-Prevention-2020 | spa |
dc.relation.references | 4. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209-249. doi:10.3322/caac.21660 | spa |
dc.relation.references | 5. United Nations. Sustainable development goals. Accessed March 3, 2021. https://sdgs.un.org | spa |
dc.relation.references | 6. NCD Countdown 2030 Collaborators. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards sustainable development goal target 3.4. Lancet. 2018;392(10152):1072-1088. doi:10.1016/S0140-6736(18)31992-5 | spa |
dc.relation.references | 7. NCD Countdown 2030 Collaborators. NCD Countdown 2030: pathways to achieving sustainable development goal target 3.4. Lancet. 2020;396(10255):918-934. doi:10.1016/S0140-6736(20)31761-X | spa |
dc.relation.references | 8. Kuderer NM, Choueiri TK, Shah DP, et al; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918. doi:10.1016/S0140-6736(20)31187-9 | spa |
dc.relation.references | 9. Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21(8):1023-1034. doi:10.1016/S1470-2045(20)30388-0 | spa |
dc.relation.references | 10. Sharpless NE. COVID-19 and cancer. Science. 2020;368(6497):1290. doi:10.1126/science.abd3377 | spa |
dc.relation.references | 11. Addai BW, Ngwa W. COVID-19 and cancer in Africa. Science. 2021;371(6524):25-27. doi:10.1126/science.abd1016 | spa |
dc.relation.references | 12. Sato Y, Fujiwara Y, Fukuda N, et al; COVID-19 Working Group of The Cancer Institute Hospital of Japanese Foundation for Cancer Research. Changes in treatment behavior during the COVID-19 pandemic among patients at a cancer hospital. Cancer Cell. 2021;39(2):130-131. doi:10.1016/j.ccell.2021.01.002 | spa |
dc.relation.references | 13. General Assembly of the United Nations. Prevention and control of non-communicable diseases. Accessed July 1, 2021. https://www.un.org/pga/72/event-latest/prevention-of-non-communicable-diseases/ | spa |
dc.relation.references | 14. United Nations. Resolution adopted by the General Assembly on 10 October 2019. Accessed March 3, 2021. https://undocs.org/en/A/RES/74/2 | spa |
dc.relation.references | 15. United Nations. The UN high-level meeting on universal health coverage. Accessed March 3, 2021. https://www.uhc2030.org/un-hlm-2019/ | spa |
dc.relation.references | 16. Anderson BO, Ilbawi AM, Fidarova E, et al. The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases. Lancet Oncol. 2021;22(5):578-581. doi:10.1016/S1470-2045(21)00071-1 | spa |
dc.relation.references | 17. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Accessed February 16, 2021. https://www.who.int/publications-detail-redirect/9789240014107 | spa |
dc.relation.references | 18. World Health Organization. Global initiative for childhood cancer. Accessed July 1, 2021. https://www.who.int/publications/m/item/global-initiative-for-childhood-cancer | spa |
dc.relation.references | 19. Bray F, Colombet M, Mery L, et al. Cancer incidence in five continents. vol XI (electronic version). Accessed March 1, 2021. https://ci5.iarc.fr | spa |
dc.relation.references | 20. Vos T, Lim SS, Abbafati C, et al; GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222. doi:10.1016/S0140-6736(20)30925-9 | spa |
dc.relation.references | 21. Wang H, Abbas KM, Abbasifard M, et al; GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1160-1203. doi:10.1016/S0140-6736(20)30977-6 | spa |
dc.relation.references | 22. Fitzmaurice C, Abate D, Abbasi N, et al; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2019;5(12):1749-1768. doi:10.1001/jamaoncol.2019.2996 | spa |
dc.relation.references | 23. Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2018;4(11):1553-1568. doi:10.1001/jamaoncol.2018.2706 | spa |
dc.relation.references | 24. Fitzmaurice C, Allen C, Barber RM, et al; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncology. 2017;3(4):524-548. doi:10.1001/jamaoncol.2016.5688 | spa |
dc.relation.references | 25. Fitzmaurice C, Dicker D, Pain A, et al; Global Burden of Disease Cancer Collaboration. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505-527. doi:10.1001/jamaoncol.2015.0735 | spa |
dc.relation.references | 26. Murray CJL, Aravkin AY, Zheng P, et al; GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223-1249. doi:10.1016/S0140-6736(20)30752-2 | spa |
dc.relation.references | 27. Stevens GA, Alkema L, Black RE, et al; GATHER Working Group. Guidelines for accurate and transparent health estimates reporting: the GATHER statement. Lancet. 2016;388(10062):e19-e23. doi:10.1016/S0140-6736(16)30388-9 | spa |
dc.relation.references | 28. World Health Organization. International Classification of Diseases: Ninth Revision, basic tabulation list with alphabetic index. Accessed March 1, 2021. https://apps.who.int/iris/handle/10665/39473 | spa |
dc.relation.references | 29. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th revision, 2nd edition. Accessed March 1, 2021. https://apps.who.int/iris/handle/10665/42980 | spa |
dc.relation.references | 30. Naghavi M, Makela S, Foreman K, O’Brien J, Pourmalek F, Lozano R. Algorithms for enhancing public health utility of national causes-of-death data. Popul Health Metr. 2010;8(1):9. doi:10.1186/1478-7954-8-9 | spa |
dc.relation.references | 31. Percy C, Ries LG, Van Holten VD. The accuracy of liver cancer as the underlying cause of death on death certificates. Public Health Rep. 1990;105(4):361-367. | spa |
dc.relation.references | 32. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069-1080. doi:10.1111/j.1365-2133.2012.10830.x | spa |
dc.relation.references | 33. Barber RM, Fullman N, Sorensen RJD, et al; GBD 2015 Healthcare Access and Quality Collaborators. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet. 2017;390(10091):231-266. doi:10.1016/S0140-6736(17)30818-8 | spa |
dc.relation.references | 34. Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of death: an integrated approach using CODEm. Popul Health Metr. 2012;10:1. doi:10.1186/1478-7954-10-1 | spa |
dc.relation.references | 35. Reitsma MB, Fullman N, Ng M, et al; GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017;389(10082):1885-1906. doi:10.1016/S0140-6736(17)30819-X | spa |
dc.relation.references | 36. Reitsma MB, Kendrick PJ, Ababneh E, et al; GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet. 2021;397(10292):2337-2360. doi:10.1016/S0140-6736(21)01169-7 | spa |
dc.relation.references | 37. Flor LS, Reitsma MB, Gupta V, Ng M, Gakidou E. The effects of tobacco control policies on global smoking prevalence. Nat Med. 2021;27(2):239-243. doi:10.1038/s41591-020-01210-8 | spa |
dc.relation.references | 38. World Health Organization. WHO report on cancer: setting priorities, investing wisely and providing care for all. Accessed February 18, 2021. https://www.who.int/publications-detail-redirect/who-report-on-cancer-setting-priorities-investing-wisely-and-providing-care-for-all | spa |
dc.relation.references | 39. GBD 2019 Universal Health Coverage Collaborators. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1250-1284. doi:10.1016/S0140-6736(20)30750-9 | spa |
dc.relation.references | 40. Cavalli F. Tackling cancer: time for a global response. Lancet. 2016;387(10018):e13-e14. doi:10.1016/S0140-6736(16)00233-6 | spa |
dc.relation.references | 41. Allemani C, Matsuda T, Di Carlo V, et al; CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-1075. doi:10.1016/S0140-6736(17)33326-3 | spa |
dc.relation.references | 42. Sankaranarayanan R. Screening for cancer in low- and middle-income countries. Ann Glob Health. 2014;80(5):412-417. doi:10.1016/j.aogh.2014.09.014 | spa |
dc.relation.references | 43. Shah SC, Kayamba V, Peek RM Jr, Heimburger D. Cancer control in low- and middle-income countries: is it time to consider screening? J Glob Oncol. 2019;5:1-8. doi:10.1200/JGO.18.00200 | spa |
dc.relation.references | 44. Brand NR, Qu LG, Chao A, Ilbawi AM. Delays and barriers to cancer care in low- and middle-income countries: a systematic review. Oncologist. 2019;24(12):e1371-e1380. doi:10.1634/theoncologist.2019-0057 | spa |
dc.relation.references | 45. Hricak H, Abdel-Wahab M, Atun R, et al. Medical imaging and nuclear medicine: a Lancet Oncology commission. Lancet Oncol. 2021;22(4):e136-e172. doi:10.1016/S1470-2045(20)30751-8 | spa |
dc.relation.references | 46. Cortes J, Perez-García JM, Llombart-Cussac A, et al. Enhancing global access to cancer medicines. CA Cancer J Clin. 2020;70(2):105-124. doi:10.3322/caac.21597 | spa |
dc.relation.references | 47. Martei YM, Iwamoto K, Barr RD, Wiernkowski JT, Robertson J. Shortages and price variability of essential cytotoxic medicines for treating children with cancers. BMJ Glob Health. 2020;5(11):e003282. doi:10.1136/bmjgh-2020-003282 | spa |
dc.relation.references | 48. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363-385. doi:10.3322/caac.21565 | spa |
dc.relation.references | 49. Mollica MA, Falisi AL, Geiger AM, et al. Survivorship objectives in comprehensive cancer control plans: a systematic review. J Cancer Surviv. 2020;14(2):235-243. doi:10.1007/s11764-019-00832-3 | spa |
dc.relation.references | 50. Dagenais GR, Leong DP, Rangarajan S, et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet. 2020;395(10226):785-794. doi:10.1016/S0140-6736(19)32007-0 | spa |
dc.relation.references | 51. Roth GA, Mensah GA, Johnson CO, et al; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021. doi:10.1016/j.jacc.2020.11.010 | spa |
dc.relation.references | 52. Franceschi S, Wild CP. Meeting the global demands of epidemiologic transition—the indispensable role of cancer prevention. Mol Oncol. 2013;7(1):1-13. doi:10.1016/j.molonc.2012.10.010 | spa |
dc.relation.references | 53. World Health Organization. Cancer control: a global snapshot in 2015: summary of results from the 2015 WHO NCD Country Capacity Survey. Accessed July 1, 2021. https://apps.who.int/iris/handle/10665/326369 | spa |
dc.relation.references | 54. International Cancer Control Partnership. Developing a NCCP. Accessed July 1, 2021. https://www.iccp-portal.org/developing-nccp | spa |
dc.relation.references | 55. World Health Organization. National cancer control programmes: policies and managerial guidelines. Accessed July 1, 2021. https://www.who.int/publications/i/item/national-cancer-control-programmes | spa |
dc.relation.references | 56. Oar A, Moraes FY, Romero Y, Ilbawi A, Yap ML. Core elements of national cancer control plans: a tool to support plan development and review. Lancet Oncol. 2019;20(11):e645-e652. doi:10.1016/S1470-2045(19)30404-8 | spa |
dc.relation.references | 57. Romero Y, Trapani D, Johnson S, et al. National cancer control plans: a global analysis. Lancet Oncol. 2018;19(10):e546-e555. doi:10.1016/S1470-2045(18)30681-8 | spa |
dc.relation.references | 58. Stulac S, Binagwaho A, Tapela NM, et al. Capacity building for oncology programmes in sub-Saharan Africa: the Rwanda experience. Lancet Oncol. 2015;16(8):e405-e413. doi:10.1016/S1470-2045(15)00161-8 | spa |
dc.relation.references | 59. Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, et al. Progress and remaining challenges for cancer control in Latin America and the Caribbean. Lancet Oncol. 2015;16(14):1405-1438. doi:10.1016/S1470-2045(15)00218-1 | spa |
dc.relation.references | 60. Znaor A, Eser S, Anton-Culver H, et al. Cancer surveillance in northern Africa, and central and western Asia: challenges and strategies in support of developing cancer registries. Lancet Oncol. 2018;19(2):e85-e92. doi:10.1016/S1470-2045(18)30019-6 | spa |
dc.relation.references | 61. WHO International Agency for Research on Cancer. The global initiative for cancer registry development. Accessed February 16, 2021. https://gicr.iarc.fr/about-the-gicr/ | spa |
dc.relation.references | 62. Piñeros M, Znaor A, Mery L, Bray F. A global cancer surveillance framework within noncommunicable disease surveillance: making the case for population-based cancer registries. Epidemiol Rev. 2017;39(1):161-169. doi:10.1093/epirev/mxx003 | spa |
dc.relation.references | 63. Suh E, Stratton KL, Leisenring WM, et al. Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol. 2020;21(3):421-435. doi:10.1016/S1470-2045(19)30800-9 | spa |
dc.subject.proposal | Cancer | eng |
dc.subject.proposal | Mortality | eng |
dc.subject.proposal | Disability | eng |
dc.title.translated | A systematic analysis for the global burden of disease study 2019 | |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | spa |
dc.type.content | Text | spa |
dc.type.driver | info:eu-repo/semantics/article | spa |
dc.type.redcol | http://purl.org/redcol/resource_type/ART | spa |
dc.type.version | info:eu-repo/semantics/publishedVersion | spa |
dc.relation.citationendpage | 444 | spa |
dc.relation.citationstartpage | 420 | spa |
dc.relation.citationissue | 3 | spa |
dc.relation.citationvolume | 8 | spa |
dc.type.coarversion | http://purl.org/coar/version/c_ab4af688f83e57aa | spa |
dc.rights.coar | http://purl.org/coar/access_right/c_f1cf | spa |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos científicos [3154]
Artículos de investigación publicados por miembros de la comunidad universitaria.